<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00823303</url>
  </required_header>
  <id_info>
    <org_study_id>22095</org_study_id>
    <nct_id>NCT00823303</nct_id>
  </id_info>
  <brief_title>Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT)</brief_title>
  <acronym>PACE</acronym>
  <official_title>A Phase 4 Randomized Multicenter Open Label Trial of Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3 or 4 Ckd Patients With Secondary Hyperparathyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Henry Ford Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Feinberg School of Medicine, Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NorthShore University HealthSystem</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Secondary Hyperparathyroidism (SHPT) occurs in many patients with kidney disease and leads to
      bone disease. Active forms of vitamin D, calcitriol and paricalcitol, treat SHPT, but may
      have different effects on blood calcium. This study will randomize patients with SHPT and
      stage 3 or 4 CKD to treatment with calcitriol or paricalcitol, and monitor patients for the
      incidence of high blood calcium, and effectiveness of SHPT treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      General Design

        -  Open label, active comparator, multicenter, parallel group, phase 4 study of
           paricalcitol versus calcitriol for suppression of PTH in stage 3 and 4 CKD patients with
           SHPT.

        -  Total study duration is 26 weeks (1 week screening, 24 weeks active medications, 1 week
           follow up.

        -  Patients meeting inclusion/exclusion criteria including baseline laboratory results will
           be randomized to paricalcitol or calcitriol, and enter a 24 weeks treatment phase.
           Visits, including safety and efficacy laboratory tests will be at weeks 4, 8, 12, 18,
           and 24. A follow up visit will be performed 1 week after stopping study medication.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed Hypercalcemia</measure>
    <time_frame>24 week treatment period</time_frame>
    <description>Serum Calcium 10.5 mg/dL or higher, confirmed by repeat measurement.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Secondary Hyperparathyroidism</condition>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Paricalcitol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>titrated to achieve 40-60% PTH suppression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcitriol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>titrated to achieve 40-60% PTH suppression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paricalcitol</intervention_name>
    <description>1 mcg daily, adjusted to achieve 40-60% PTH suppression</description>
    <arm_group_label>Paricalcitol</arm_group_label>
    <other_name>Zemplar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcitriol</intervention_name>
    <description>0.25 mcg daily, adjusted to achieve 40-60% PTH suppression</description>
    <arm_group_label>Calcitriol</arm_group_label>
    <other_name>Rocaltrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Age &gt;18; Able to give informed consent

          2. Chronic kidney disease, and estimated GFR 15 to 60 ml/min using the abbreviated MDRD
             equation

          3. intact PTH (iPTH) &gt;120 pg/ml at baseline

          4. albumin corrected calcium &gt; 8.5 mg/dL to &lt; 10.0 mg/dL at baseline

          5. Phosphorus &lt; 4.6 mg/dL at baseline

          6. If on a phosphorus binder; no change in dose within the 4 weeks prior to screening

        Exclusion Criteria

          1. Receiving any active form of vitamin D within 4 weeks prior to screening (calcitriol,
             doxercalciferol; paricalcitol; alfacalcidol)

          2. Receiving &gt;50,000 IU per month of ergocalciferol or &gt; 1000 IU of cholecalciferol per
             day within the previous 30 days.

          3. history of primary HPT

          4. On prednisone &gt; 30 days within the previous 6 months

          5. receiving bisphosphonates or calcitonin within the previous 12 months

          6. Non-elective hospitalization within the previous 30 days.

          7. Expected to initiate dialysis or receive a kidney transplant within the next 6 mo.

          8. History of renal or other organ transplant

          9. History of parathyroidectomy or previous diagnosis of primary hyperparathyroidism

         10. Receiving cinacalcet within 4 weeks prior to screening.

         11. An active drug/alcohol dependence or abuse history

         12. History of non-compliance with visits or medications that preclude study compliance in
             the opinion of the investigator

         13. Pregnant, or able to become pregnant and unwilling to use a birth control method
             considered reliable by the principal investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel W Coyne, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northshore University Health System</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Coyne DW, Goldberg S, Faber M, Ghossein C, Sprague SM. A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD. Clin J Am Soc Nephrol. 2014 Sep 5;9(9):1620-6. doi: 10.2215/CJN.10661013. Epub 2014 Jun 26.</citation>
    <PMID>24970869</PMID>
  </results_reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2008</study_first_submitted>
  <study_first_submitted_qc>January 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2009</study_first_posted>
  <results_first_submitted>June 5, 2014</results_first_submitted>
  <results_first_submitted_qc>July 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 5, 2014</results_first_posted>
  <last_update_submitted>August 4, 2014</last_update_submitted>
  <last_update_submitted_qc>August 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Daniel W. Coyne</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>PTH</keyword>
  <keyword>Active Vitamin D</keyword>
  <keyword>hypercalcemia</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitriol</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Paricalcitol</title>
          <description>titrated to achieve 40-60% PTH suppression
Paricalcitol: 1 mcg daily, adjusted to achieve 40-60% PTH suppression</description>
        </group>
        <group group_id="P2">
          <title>Calcitriol</title>
          <description>titrated to achieve 40-60% PTH suppression
Calcitriol: 0.25 mcg daily, adjusted to achieve 40-60% PTH suppression</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Stage 3 and 4 CKD with SHPT, age &gt;18, a stable dose of phosphate binder (if receiving a binder), estimated glomerular filtration rate (eGFR) of 15-59 mL/min using the abbreviated MDRD equation, PTH &gt;120 pg/mL, albumin-corrected calcium &gt;8.5 mg/dL and &lt;10.0 mg/dL, phosphorus &lt;4.6 mg/dL.</population>
      <group_list>
        <group group_id="B1">
          <title>Paricalcitol</title>
          <description>titrated to achieve 40-60% PTH suppression
Paricalcitol: 1 mcg daily, adjusted to achieve 40-60% PTH suppression</description>
        </group>
        <group group_id="B2">
          <title>Calcitriol</title>
          <description>titrated to achieve 40-60% PTH suppression
Calcitriol: 0.25 mcg daily, adjusted to achieve 40-60% PTH suppression</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
            <count group_id="B2" value="56"/>
            <count group_id="B3" value="110"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.6" spread="13.2"/>
                    <measurement group_id="B2" value="64.7" spread="12.6"/>
                    <measurement group_id="B3" value="65.6" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Confirmed Hypercalcemia</title>
        <description>Serum Calcium 10.5 mg/dL or higher, confirmed by repeat measurement.</description>
        <time_frame>24 week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>titrated to achieve 40-60% PTH suppression
Paricalcitol: 1 mcg daily, adjusted to achieve 40-60% PTH suppression</description>
          </group>
          <group group_id="O2">
            <title>Calcitriol</title>
            <description>titrated to achieve 40-60% PTH suppression
Calcitriol: 0.25 mcg daily, adjusted to achieve 40-60% PTH suppression</description>
          </group>
        </group_list>
        <measure>
          <title>Confirmed Hypercalcemia</title>
          <description>Serum Calcium 10.5 mg/dL or higher, confirmed by repeat measurement.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>On the basis of prior published reports, we estimated a 5% rate of hypercalcemia with paricalcitol and a 30% rate with calcitriol. To have a 90% power to detect a difference at the P=0.05 confidence level, 42 patients per group were needed. Assuming a 30% dropout rate over the course of the study, we planned to randomize 110 patients.</non_inferiority_desc>
            <p_value>0.36</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Paricalcitol</title>
          <description>titrated to achieve 40-60% PTH suppression
Paricalcitol: 1 mcg daily, adjusted to achieve 40-60% PTH suppression</description>
        </group>
        <group group_id="E2">
          <title>Calcitriol</title>
          <description>titrated to achieve 40-60% PTH suppression
Calcitriol: 0.25 mcg daily, adjusted to achieve 40-60% PTH suppression</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <description>Hypercalcemia requiring or prolonging hospitalization</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="53"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Daniel W. Coyne</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>3143627211</phone>
      <email>dcoyne@dom.wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

